Published in PeerJ on September 25, 2014
Bacteriophage Procurement for Therapeutic Purposes. Front Microbiol (2016) 0.82
Adapting Drug Approval Pathways for Bacteriophage-Based Therapeutics. Front Microbiol (2016) 0.80
Ecology of Anti-Biofilm Agents I: Antibiotics versus Bacteriophages. Pharmaceuticals (Basel) (2015) 0.79
Ecology of Anti-Biofilm Agents II: Bacteriophage Exploitation and Biocontrol of Biofilm Bacteria. Pharmaceuticals (Basel) (2015) 0.79
Parasite diversity drives rapid host dynamics and evolution of resistance in a bacteria-phage system. Evolution (2016) 0.76
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol (2006) 40.15
Interference Between Bacterial Viruses: III. The Mutual Exclusion Effect and the Depressor Effect. J Bacteriol (1945) 23.24
Complete nucleotide sequence of bacteriophage T7 DNA and the locations of T7 genetic elements. J Mol Biol (1983) 19.98
Assembling millions of short DNA sequences using SSAKE. Bioinformatics (2006) 18.71
Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci U S A (2007) 2.87
Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One (2009) 2.61
Testing optimality with experimental evolution: lysis time in a bacteriophage. Evolution (2007) 2.10
Phage cocktails and the future of phage therapy. Future Microbiol (2013) 1.75
Polysaccharide lyases. FEMS Microbiol Rev (1995) 1.57
Phage choice, isolation, and preparation for phage therapy. Curr Pharm Biotechnol (2010) 1.50
Rate of translocation of bacteriophage T7 DNA across the membranes of Escherichia coli. J Bacteriol (1995) 1.49
Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms. Appl Environ Microbiol (2001) 1.41
Bacteriophage and associated polysaccharide depolymerases--novel tools for study of bacterial biofilms. J Appl Microbiol (1998) 1.41
Prevention and cure of systemic Escherichia coli K1 infection by modification of the bacterial phenotype. Antimicrob Agents Chemother (2004) 1.38
The use of phages for the removal of infectious biofilms. Curr Pharm Biotechnol (2008) 1.25
The T7-related Pseudomonas putida phage φ15 displays virion-associated biofilm degradation properties. PLoS One (2011) 1.25
Predicting evolution from genomics: experimental evolution of bacteriophage T7. Heredity (Edinb) (2008) 1.22
Escherichia coli capsule bacteriophages. IV. Free capsule depolymerase 29. J Virol (1975) 1.12
A tale of tails: Sialidase is key to success in a model of phage therapy against K1-capsulated Escherichia coli. Virology (2009) 1.05
Bacteriophages LIMElight and LIMEzero of Pantoea agglomerans, belonging to the "phiKMV-like viruses". Appl Environ Microbiol (2011) 0.97
Phenotypic resistance and the dynamics of bacterial escape from phage control. PLoS One (2014) 0.91
Evolutionary principles and synthetic biology: avoiding a molecular tragedy of the commons with an engineered phage. J Biol Eng (2012) 0.87
Enzymic hydrolysis of colanic acid. Eur J Biochem (1971) 0.85
Identification and removal of colanic acid from plasmid DNA preparations: implications for gene therapy. Gene Ther (2010) 0.84
Thermal treatment of the bacteriophage lysate of Klebsiella pneumoniae B5055 as a step for the purification of capsular depolymerase enzyme. J Virol Methods (2011) 0.81